Oceanpine Capital investee company——AnlongBio announced the completion of a Series C financing worth five hundreds of millions of yuan. This round was led by GL Capital Group, Broad Vision Funds and Oceanpine Capital, with old shareholders support from Everest Venture Capital and Jiangsu Tuobang Investment. The funds raised will be used to subsequent clinical development of a number of blockbusters In-vitro diagnosis (IVD) new products such as ctDNA and early tumor screening, and to open up direct sales channels for more than 500 tertiary hospitals.
AnlongBio, aims to provide various genetic medicines to fulfill the unmet medical need in China, AnlongBio develops AAV gene therapies within house technologies from vector discoveries to manufacturing and clinical approval.
AnlongBio is actively looking for partnership in genetic medicine/gene therapy around the world. We focus on genetic medicines including AAV portfolios, Lenti-virus cell therapies, RNA medicines or Oncolytic virus etc. Along with AnlongMed, the renown biopharma VC in China, we are interested in licensing, JV, co-development, invest, or any other forms of collaborations.
Source：Oceanpine Capital
